A Phase 3, Multicenter, Long-term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement

Trial Profile

A Phase 3, Multicenter, Long-term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Tanezumab (Primary) ; Celecoxib; Diclofenac; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TJR-FOLLOW-UP
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Oct 2017 Planned End Date changed from 12 Jul 2019 to 12 Aug 2019.
    • 27 Oct 2017 Planned primary completion date changed from 12 Jul 2019 to 12 Aug 2019.
    • 16 Mar 2017 Planned End Date changed from 1 Jul 2019 to 12 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top